Condition

Anatomic Stage III Breast Cancer AJCC v8

ClinicalTrials.gov condition label

Clinical trials158

Recruiting43

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast CancerNCT07741968 · 2027-02-22

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC TrialNCT07474090 · 2026-10-02

A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer SurvivorsNCT07699991 · 2026-09-01

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast CancerNCT05874297 · 2026-07-15

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer PatientsNCT07460752 · 2026-05-22

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialNCT07191717 · 2026-05-18

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS TrialNCT07443943 · 2026-04-22

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerNCT06434064 · 2026-03-03

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialNCT07158021 · 2026-01-22

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerNCT06324240 · 2025-12-02

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 TrialNCT06999798 · 2025-08-29

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast CancerNCT06954831 · 2025-08-28

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer PatientsNCT07341503 · 2025-08-18

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone LossNCT07044310 · 2025-07-25

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast CancerNCT06635980 · 2025-05-14

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! TrialNCT05930483 · 2025-04-08

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing ChemotherapyNCT06763328 · 2024-12-16

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast CancerNCT06534125 · 2024-12-12

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast CancerNCT06582615 · 2024-10-28

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialNCT06042569 · 2024-09-16

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerNCT05741164 · 2024-09-01

Prevention of Frailty With Fisetin and Exercise in Breast Cancer SurvivorsNCT06113016 · 2024-07-23

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor TherapyNCT06401889 · 2024-07-19

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsNCT06388122 · 2024-04-30

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · 2023-08-10

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerNCT05422794 · 2023-05-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07

Fisetin to Improve Physical Function in Stage I-III Breast Cancer SurvivorsNCT05595499 · 2023-03-27

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerNCT05417308 · 2023-03-01

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast CancerNCT05677802 · 2022-12-14

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast CancerNCT05464810 · 2022-09-02

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before SurgeryNCT05327608 · 2022-07-28

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerNCT04329065 · 2022-04-20

Breast Cancer Survivorship BiorepositoryNCT05786664 · 2022-04-11

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast CancerNCT04517838 · 2020-07-31

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNCT04090567 · 2020-07-28

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or MelanomaNCT03941756 · 2018-08-14

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast CancerNCT02918474 · 2017-04-28

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE TrialNCT07590583 · 2026-12-19

NOT_YET_RECRUITING

Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer PatientsNCT07594678 · 2026-11-15

NOT_YET_RECRUITING

Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C TrialNCT07723235 · 2026-10-10

NOT_YET_RECRUITING

US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNCT07862751 · 2026-10-01

NOT_YET_RECRUITING

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenNCT07721259 · 2026-09-30

NOT_YET_RECRUITING

Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase InhibitorsNCT07769047 · 2026-09-01

NOT_YET_RECRUITING

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast CancerNCT07226102 · 2026-07-16

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast CancerNCT07136493 · 2026-05-12

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerNCT06590558 · 2025-08-04

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24

Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND TrialNCT06643455 · 2025-05-16

Integrative Approaches for Cancer Survivorship (IACS3)NCT06633926 · 2025-03-31

ACTIVE_NOT_RECRUITING

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerNCT05539365 · 2025-02-01

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT TrialNCT06617455 · 2024-10-31

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer SurvivorsNCT06392789 · 2024-10-04

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving ChemotherapyNCT06238986 · 2024-03-22

An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition InformationNCT06193070 · 2024-03-07

Common interventions

Leading sponsors

Mayo Clinic28 M.D. Anderson Cancer Center23 National Cancer Institute (NCI)20 Ohio State University Comprehensive Cancer Center17 City of Hope Medical Center9 Fred Hutchinson Cancer Center8 Emory University7 University of Washington7 Jonsson Comprehensive Cancer Center5 Alliance for Clinical Trials in Oncology3 OHSU Knight Cancer Institute3 Roswell Park Cancer Institute3 Thomas Jefferson University3 University of California, San Francisco3 University of Michigan Rogel Cancer Center3

Trial status mix

RECRUITING43

COMPLETED41

ACTIVE_NOT_RECRUITING32

TERMINATED19

WITHDRAWN13

NOT_YET_RECRUITING6

SUSPENDED3

UNKNOWN1

Phase mix

NA48

PHASE247

PHASE132

PHASE38

EARLY_PHASE17

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.